{
    "nctId": "NCT05367739",
    "briefTitle": "Real World Study on the Efficacy and Safety of Anti-HER2 Therapy",
    "officialTitle": "A Real-world Observational Study on the Efficacy and Safety of Anti HER2 Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old, voluntary consent and signed written informed consent.\n* ECOG 0\\~2.\n* Diagnosis of locally advanced (stage IIIB or IIIC) or metastatic (stage IV) breast cancer.\n* At least one measurable disease lesion before treatment.\n* Anticipated survival time is longer than three months.\n* Pathological and IHC reports for ER, PR, HER2 and Ki67 are available.\n* For women with fertility, the pregnancy test before administration was negative, and agreed to take appropriate measures to avoid pregnancy during the study treatment and at least half a year after the end of treatment\n* There are traceable medical records during treatment.\n\nExclusion Criteria:\n\n* Pregnant or lactating women. Active infection requiring systemic treatment\u3002\n* HIV positive\n* Suffering from or suspected of suffering from central nervous system diseases.\n* Serious heart disease.\n* Pulmonary lymphatic involvement leads to pulmonary dysfunction and requires active treatment, including the use of oxygen\n* The investigator considered that the patient was not suitable for in this study, with any other situation.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}